Scarica l'app Stockscreener
23.25
0.61%
0.14
Dopo l'orario di chiusura:
23.25
Precedente Chiudi:
$23.11
Aprire:
$23.98
Volume 24 ore:
1.85M
Relative Volume:
2.14
Capitalizzazione di mercato:
$92.67M
Reddito:
-
Utile/perdita netta:
$-24.77M
Rapporto P/E:
-31.85
EPS:
-0.73
Flusso di cassa netto:
$-17.36M
1 W Prestazione:
+200.78%
1M Prestazione:
+210.41%
6M Prestazione:
+164.20%
1 anno Prestazione:
+121.43%
Intervallo 1D:
$23.20
$30.30
Intervallo di 1 settimana:
$20.20
$76.00
Portata 52W:
$4.5601
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
Nome
Mink Therapeutics Inc
Settore
Industria
Telefono
212-994-8250
Indirizzo
149 FIFTH AVENUE, NEW YORK
Confronta INKT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
23.25 | 30.81M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-14 | Downgrade | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc Borsa (INKT) Ultime notizie
MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress - Oncodaily
MiNK Therapeutics (NASDAQ:INKT) Rating Lowered to “Neutral” at HC Wainwright - Defense World
Mink Therapeutics Shares Slide After Announcing $50 Million Stock Offering - MSN
Mink Therapeutics stock tumbles on $50 million stock offering - Investing.com
Agenus unit, MiNK surges after peer-reviewed data for lead drug - MSN
What makes MiNK Therapeutics Inc. stock price move sharplyAI Powered Stock Call - Newser
How MiNK Therapeutics Inc. stock performs during market volatilityLow Risk Entry Points - Newser
Why MiNK Therapeutics Inc. stock attracts strong analyst attentionFree Market Analysis Group - Newser
MiNK Therapeutics stock rating downgraded to Neutral by H.C. Wainwright - Investing.com UK
MiNK Therapeutics Plummets 29%—What’s Driving the Sell-Off? - AInvest
MiNK Therapeutics Plummets 28.59% — What’s Driving the Sell-Off? - AInvest
MiNK Therapeutics publishes research on CAR-iNKT cell therapy By Investing.com - Investing.com South Africa
Mink Therapeutics stock tumbles on $50 million stock offering By Investing.com - Investing.com Nigeria
MiNK Therapeutics enters $50 million at-the-market sales agreement with B. Riley Securities By Investing.com - Investing.com South Africa
MiNK Therapeutics enters $50 million at-the-market sales agreement with B. Riley Securities - Investing.com Canada
MiNK Therapeutics Announces Frontiers in Immunology - GlobeNewswire
MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy - TradingView
Revolutionary iNKT Cell Therapy Achieves 2-Year Complete Remission in Treatment-Resistant Cancer - Stock Titan
MiNK Therapeutics Announces Clinical Trial Success - The Globe and Mail
INKT’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
MiNK Therapeutics Enters $50M Sales Agreement with B. Riley - TipRanks
MiNK Therapeutics Plunges 24.87% After William Blair Downgrade - AInvest
INKT sets up $50M ATM with B. Riley, adds financing flexibility | INKT SEC FilingForm 8-K - Stock Titan
Pharmaceutical Stocks Worth Watching – July 13th - Defense World
MiNK Therapeutics Plummets to 449th in Trading Volume Amid 91.42% Decline - AInvest
MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy - MSN
MiNK Therapeutics Downgraded to Market Perform by William Blair - AInvest
MiNK Therapeutics stock maintains Buy rating at H.C. Wainwright after case study publication - Investing.com Canada
MiNK Therapeutics: Moving Out Of The Hunt's Early Days (NASDAQ:INKT) - Seeking Alpha
MiNK Therapeutics Plummets 28%—What's Driving the Freefall? - AInvest
MiNK Therapeutics Plummets 43%—What’s Driving the Freefall? - AInvest
William Blair downgrades MiNK Therapeutics stock to Market Perform after 700% surge - Investing.com Canada
MiNK Therapeutics Shares Drop Sharply Following William Blair Downgrade - MSN
William Blair downgrades MiNK on valuation after 700% rally - TipRanks
MiNK Therapeutics reports publication of case study on iNKT cell therapy - Investing.com
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
MiNK Therapeutics reports publication of case study on iNKT cell therapy By Investing.com - Investing.com South Africa
MiNK Therapeutics stock falls after William Blair downgrade By Investing.com - Investing.com Canada
MiNK Therapeutics, Inc.'s (NASDAQ:INKT) biggest owners are public companies who got richer after stock soared 815% last week - Yahoo Finance
Pharmaceutical Stocks To Research – July 12th - Defense World
Why Did MiNK Therapeutics Plunge 31.92% After William Blair Downgrade? - AInvest
Small Cap Stocks To Follow Now – July 12th - Defense World
Top Medical Stocks To Follow Now – July 12th - Defense World
Value Stocks To Watch Now – July 12th - Defense World
INKT Stock Price and Chart — NASDAQ:INKT - TradingView
MiNK Therapeutics, Inc.'s (NASDAQ:INKT) biggest owners are public companies who got richer after stock soared 787% last week - simplywall.st
MiNK Therapeutics: Leading the Allogeneic Cell Therapy Revolution with AgenT-797's Durable Solid Tumor Responses - AInvest
MiNK Therapeutics stock surges 730% after releasing positive CR data from its AgenT-797 trial. - AInvest
MiNK Therapeutics: AgenT-797 Solidifies Itself As iNKT Cell Therapy With Latest CR Data - Seeking Alpha
Pharmaceutical Stocks To Keep An Eye On – July 11th - Defense World
Best Medical Stocks To Keep An Eye On – July 11th - Defense World
Mink Therapeutics Inc Azioni (INKT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):